Cingulate Inc., a leading biopharmaceutical company, has recently announced the receipt of a significant fiscal year 2025 PDUFA fee waiver from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for CTx-1301, a promising treatment for Attention Deficit Hyperactivity Disorder (ADHD). This waiver, granted through the small business provision of the FD&C Act, will save Cingulate over $4 million and enhance its financial position as it moves towards commercializing CTx-1301. With a focus on leveraging its PTR drug delivery platform technology, Cingulate aims to develop innovative pharmaceutical products to address the needs of patients with challenging treatment regimens and suboptimal outcomes in various therapeutic areas. For more information on Cingulate Inc. and its groundbreaking initiatives, visit Cingulate.com.
Read more from finance.yahoo.com